Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Evolution of Metastases in Space and Time under Immune Selection.

Angelova M, Mlecnik B, Vasaturo A, Bindea G, Fredriksen T, Lafontaine L, Buttard B, Morgand E, Bruni D, Jouret-Mourin A, Hubert C, Kartheuser A, Humblet Y, Ceccarelli M, Syed N, Marincola FM, Bedognetti D, Van den Eynde M, Galon J.

Cell. 2018 Oct 18;175(3):751-765.e16. doi: 10.1016/j.cell.2018.09.018. Epub 2018 Oct 11.

PMID:
30318143
2.

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.

Corcoran RB, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G, Muro K, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, Humblet Y, De Vos F, Jung AS, Brase JC, Jaeger S, Bettinger S, Mookerjee B, Rangwala F, Van Cutsem E.

Cancer Discov. 2018 Apr;8(4):428-443. doi: 10.1158/2159-8290.CD-17-1226. Epub 2018 Feb 5.

3.

Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival.

Mlecnik B, Van den Eynde M, Bindea G, Church SE, Vasaturo A, Fredriksen T, Lafontaine L, Haicheur N, Marliot F, Debetancourt D, Pairet G, Jouret-Mourin A, Gigot JF, Hubert C, Danse E, Dragean C, Carrasco J, Humblet Y, Valge-Archer V, Berger A, Pagès F, Machiels JP, Galon J.

J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx123. Erratum in: J Natl Cancer Inst. 2018 Apr 1;110(4):438.

PMID:
28922789
4.

Phenotypic variation of an ALK-positive large-cell neuroendocrine lung carcinoma with carcinoid morphology during treatment with ALK inhibitors.

Hoton D, Humblet Y, Libbrecht L.

Histopathology. 2018 Mar;72(4):707-710. doi: 10.1111/his.13388. Epub 2017 Dec 11. No abstract available.

PMID:
28888040
5.

Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study).

Ricotta R, Verrioli A, Ghezzi S, Porcu L, Grothey A, Falcone A, Van Cutsem E, Argilés G, Adenis A, Ychou M, Barone C, Bouché O, Peeters M, Humblet Y, Mineur L, Sobrero AF, Hubbard JM, Cremolini C, Prenen H, Tabernero J, Jarraya H, Mazard T, Deguelte-Lardiere S, Papadimitriou K, Van den Eynde M, Pastorino A, Redaelli D, Bencardino K, Funaioli C, Amatu A, Carlo-Stella G, Torri V, Sartore-Bianchi A, Vanzulli A, Siena S.

ESMO Open. 2017 Feb 13;1(6):e000111. doi: 10.1136/esmoopen-2016-000111. eCollection 2016.

6.

Regorafenib induced severe toxic hepatitis: characterization and discussion.

Sacré A, Lanthier N, Dano H, Aydin S, Leggenhager D, Weber A, Dekairelle AF, De Cuyper A, Gala JL, Humblet Y, Sempoux C, Van den Eynde M.

Liver Int. 2016 Nov;36(11):1590-1594. doi: 10.1111/liv.13217. Epub 2016 Sep 6.

7.

Lymph node ratio and surgical quality are strong prognostic factors of rectal cancer: results from a single referral centre.

Leonard D, Remue C, Abbes Orabi N, van Maanen A, Danse E, Dragean A, Debetancourt D, Humblet Y, Jouret-Mourin A, Maddalena F, Medina Benites A, Scalliet P, Sempoux C, Van den Eynde M, De Schoutheete JC, Kartheuser A.

Colorectal Dis. 2016 Jun;18(6):O175-84. doi: 10.1111/codi.13362.

PMID:
27128602
8.

Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).

De Grève J, Van Meerbeeck J, Vansteenkiste JF, Decoster L, Meert AP, Vuylsteke P, Focan C, Canon JL, Humblet Y, Berchem G, Colinet B, Galdermans D, Bosquée L, Vermeij J, Dewaele A, Geers C, Schallier D, Teugels E.

PLoS One. 2016 Mar 31;11(3):e0147599. doi: 10.1371/journal.pone.0147599. eCollection 2016.

9.

Ossification of a rectal tumor: an uncommon finding.

Smajda S, Danse E, Mertens de Wilmars M, Humblet Y, Kartheuser A, Jouret-Mourin A.

Acta Gastroenterol Belg. 2015 Dec;78(4):431-5.

PMID:
26712056
10.

Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.

Van Cutsem E, Joulain F, Hoff PM, Mitchell E, Ruff P, Lakomý R, Prausová J, Moiseyenko VM, van Hazel G, Cunningham D, Arnold D, Schmoll HJ, Ten Tije AJ, McKendrick J, Kröning H, Humblet Y, Grávalos C, Le-Guennec S, Andria M, Dochy E, Vishwanath RL, Macarulla T, Tabernero J.

Target Oncol. 2016 Jun;11(3):383-400. doi: 10.1007/s11523-015-0402-9.

PMID:
26706237
11.

Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone.

Carrasco J, Gizzi M, Pairet G, Lannoy V, Lefesvre P, Gigot JF, Hubert C, Jouret-Mourin A, Humblet Y, Canon JL, Sempoux C, Chapaux X, Danse E, Tinton N, Navez B, Van den Eynde M.

Br J Cancer. 2015 Nov 3;113(9):1298-304. doi: 10.1038/bjc.2015.321. Epub 2015 Oct 13.

12.

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.

Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Yoshino T, Goldberg RM, Sargent DJ, Wagner A, Laurent D, Teufel M, Jeffers M, Grothey A, Van Cutsem E.

Lancet Oncol. 2015 Aug;16(8):937-48. doi: 10.1016/S1470-2045(15)00138-2. Epub 2015 Jul 13.

PMID:
26184520
13.

Radical resection of noncolorectal liver metastases: is cure possible?

Ghammad K, Heuker D, Stainier L, Hubert C, Humblet Y, Baurain JF, Lannoy, Gigot J.

Hepatogastroenterology. 2014 Jul-Aug;61(133):1374-9. No abstract available.

PMID:
25436314
14.

Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer.

Mardjuadi FI, Carrasco J, Coche JC, Sempoux C, Jouret-Mourin A, Scalliet P, Goeminne JC, Daisne JF, Delaunoit T, Vuylsteke P, Humblet Y, Meert N, van den Eynde M, Moxhon A, Haustermans K, Canon JL, Machiels JP.

Target Oncol. 2015 Sep;10(3):375-83. doi: 10.1007/s11523-014-0342-9. Epub 2014 Oct 11.

PMID:
25304881
15.

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Smakal M, Canon JL, Rother M, Oliner KS, Tian Y, Xu F, Sidhu R.

Ann Oncol. 2014 Jul;25(7):1346-55. doi: 10.1093/annonc/mdu141. Epub 2014 Apr 8.

PMID:
24718886
16.

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.

Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD.

N Engl J Med. 2013 Sep 12;369(11):1023-34. doi: 10.1056/NEJMoa1305275.

17.

Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer.

Rougier P, Riess H, Manges R, Karasek P, Humblet Y, Barone C, Santoro A, Assadourian S, Hatteville L, Philip PA.

Eur J Cancer. 2013 Aug;49(12):2633-42. doi: 10.1016/j.ejca.2013.04.002. Epub 2013 Apr 30.

PMID:
23642329
18.

Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab.

Hubert C, Sempoux C, Humblet Y, van den Eynde M, Zech F, Leclercq I, Gigot JF.

HPB (Oxford). 2013 Nov;15(11):858-64. doi: 10.1111/hpb.12047. Epub 2013 Jan 18.

19.

Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.

Peeters M, Oliner KS, Parker A, Siena S, Van Cutsem E, Huang J, Humblet Y, Van Laethem JL, André T, Wiezorek J, Reese D, Patterson SD.

Clin Cancer Res. 2013 Apr 1;19(7):1902-12. doi: 10.1158/1078-0432.CCR-12-1913. Epub 2013 Jan 16.

20.

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D; CORRECT Study Group.

Lancet. 2013 Jan 26;381(9863):303-12. doi: 10.1016/S0140-6736(12)61900-X. Epub 2012 Nov 22.

PMID:
23177514
21.

Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study.

Van Cutsem E, Tejpar S, Vanbeckevoort D, Peeters M, Humblet Y, Gelderblom H, Vermorken JB, Viret F, Glimelius B, Gallerani E, Hendlisz A, Cats A, Moehler M, Sagaert X, Vlassak S, Schlichting M, Ciardiello F.

J Clin Oncol. 2012 Aug 10;30(23):2861-8. doi: 10.1200/JCO.2011.40.9243. Epub 2012 Jul 2.

PMID:
22753904
22.

A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer.

Bleiberg H, Vandebroek A, Deleu I, Vergauwe P, Rezaei Kalantari H, D'Haens G, Paesmans M, Peeters M, Efira A, Humblet Y.

Acta Gastroenterol Belg. 2012 Mar;75(1):14-21.

PMID:
22567742
23.

New drugs in medical oncology: new difficulties to distinguish drug-induced side effects from cancer complications: a case-report.

Seront E, Mazzeo F, Mano M, Sterckx M, Humblet Y, Machiels JP, Baurain JF.

Acta Clin Belg. 2011 Nov-Dec;66(6):426-8.

PMID:
22338305
24.

Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma.

Borbath I, Verbrugghe L, Lai R, Gigot JF, Humblet Y, Piessevaux H, Sempoux C.

Eur J Cancer. 2012 May;48(7):990-6. doi: 10.1016/j.ejca.2011.11.006. Epub 2011 Dec 1.

PMID:
22137164
25.

A phase I clinical and pharmacological study evaluating vinflunine in combination with doxorubicin as first line treatment in metastatic breast cancer.

Zaman K, Durando X, Baurain JF, Humblet Y, Mazzeo F, Bostnavaron M, Meheust N, Monnoyer-Favrel S, Machiels JP, Bauer J.

Breast Cancer Res Treat. 2011 Jun;127(3):689-96. doi: 10.1007/s10549-011-1446-x. Epub 2011 Mar 26.

PMID:
21442199
26.

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J.

J Clin Oncol. 2010 Nov 1;28(31):4697-705. doi: 10.1200/JCO.2009.27.4860. Epub 2010 Oct 4.

PMID:
20921465
27.

Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab.

Seront E, Marot L, Coche E, Gala JL, Sempoux C, Humblet Y.

Cancer Treat Rev. 2010 Feb;36 Suppl 1:S11-4. doi: 10.1016/S0305-7372(10)70002-5.

PMID:
20189054
28.

Prevalence and clinical relevance of pathological hepatic changes occurring after neoadjuvant chemotherapy for colorectal liver metastases.

Hubert C, Fervaille C, Sempoux C, Horsmans Y, Humblet Y, Machiels JP, Zech F, Ceratti A, Gigot JF.

Surgery. 2010 Feb;147(2):185-94. doi: 10.1016/j.surg.2009.01.004.

PMID:
20109620
29.

Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.

Jacobs B, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, De Schutter J, Fieuws S, Vandesompele J, Peeters M, Van Laethem JL, Humblet Y, Pénault-Llorca F, De Hertogh G, Laurent-Puig P, Van Cutsem E, Tejpar S.

J Clin Oncol. 2009 Oct 20;27(30):5068-74. doi: 10.1200/JCO.2008.21.3744. Epub 2009 Sep 8.

PMID:
19738126
30.

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.

Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang A, Cosaert J, Moore MJ.

J Clin Oncol. 2009 May 1;27(13):2231-7. doi: 10.1200/JCO.2008.20.0238. Epub 2009 Mar 23.

PMID:
19307500
31.

An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer.

de Boer R, Humblet Y, Wolf J, Nogová L, Ruffert K, Milenkova T, Smith R, Godwood A, Vansteenkiste J.

Ann Oncol. 2009 Mar;20(3):486-91. doi: 10.1093/annonc/mdn674. Epub 2008 Dec 16.

PMID:
19088171
32.

Textiloma on PET-CT.

Coche E, Humblet Y, Lonneux M.

JBR-BTR. 2008 Jul-Aug;91(4):180. No abstract available.

PMID:
18817103
33.

Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.

Personeni N, Fieuws S, Piessevaux H, De Hertogh G, De Schutter J, Biesmans B, De Roock W, Capoen A, Debiec-Rychter M, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S.

Clin Cancer Res. 2008 Sep 15;14(18):5869-76. doi: 10.1158/1078-0432.CCR-08-0449.

34.

Drug Insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer.

Mano M, Humblet Y.

Nat Clin Pract Oncol. 2008 Jul;5(7):415-25. doi: 10.1038/ncponc1136. Epub 2008 May 27. Review.

PMID:
18506165
35.

Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer.

Efficace F, Innominato PF, Bjarnason G, Coens C, Humblet Y, Tumolo S, Genet D, Tampellini M, Bottomley A, Garufi C, Focan C, Giacchetti S, Lévi F; Chronotherapy Group of the European Organisation for Research and Treatment of Cancer.

J Clin Oncol. 2008 Apr 20;26(12):2020-6. doi: 10.1200/JCO.2007.12.3117.

PMID:
18421055
36.

Bronchobiliary fistula and cholangiocarcinoma: a case report and principles of management.

Delande S, Goffette P, Verbaandert C, Rahier J, Graux C, Mazzeo F, Humblet Y, Machiels JP.

Acta Clin Belg. 2007 Nov-Dec;62(6):438-41.

PMID:
18351189
37.
38.

Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab.

Siena S, Peeters M, Van Cutsem E, Humblet Y, Conte P, Bajetta E, Comandini D, Bodoky G, Van Hazel G, Salek T, Wolf M, Devercelli G, Woolley M, Amado RG.

Br J Cancer. 2007 Dec 3;97(11):1469-74. Epub 2007 Nov 27.

39.

Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.

Tabernero J, Van Cutsem E, Díaz-Rubio E, Cervantes A, Humblet Y, André T, Van Laethem JL, Soulié P, Casado E, Verslype C, Valera JS, Tortora G, Ciardiello F, Kisker O, de Gramont A.

J Clin Oncol. 2007 Nov 20;25(33):5225-32.

PMID:
18024868
40.

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.

De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S.

Ann Oncol. 2008 Mar;19(3):508-15. Epub 2007 Nov 12.

PMID:
17998284
41.

An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.

Van Cutsem E, Siena S, Humblet Y, Canon JL, Maurel J, Bajetta E, Neyns B, Kotasek D, Santoro A, Scheithauer W, Spadafora S, Amado RG, Hogan N, Peeters M.

Ann Oncol. 2008 Jan;19(1):92-8. Epub 2007 Sep 4.

PMID:
17785764
42.

Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases?

Hubert C, Sempoux C, Horsmans Y, Rahier J, Humblet Y, Machiels JP, Ceratti A, Canon JL, Gigot JF.

Liver Int. 2007 Sep;27(7):938-43.

PMID:
17696932
43.

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG.

J Clin Oncol. 2007 May 1;25(13):1658-64.

PMID:
17470858
44.

Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.

Machiels JP, Sempoux C, Scalliet P, Coche JC, Humblet Y, Van Cutsem E, Kerger J, Canon JL, Peeters M, Aydin S, Laurent S, Kartheuser A, Coster B, Roels S, Daisne JF, Honhon B, Duck L, Kirkove C, Bonny MA, Haustermans K.

Ann Oncol. 2007 Apr;18(4):738-44. Epub 2007 Jan 5.

PMID:
17208931
45.

Prognostic factors for long-term survival in patients with thoracic metastatic disease: a 10-year experience.

Poncelet AJ, Lurquin A, Weynand B, Humblet Y, Noirhomme P; Groupe d' Oncologie Thoracique Des Cliniques Saint-Luc.

Eur J Cardiothorac Surg. 2007 Feb;31(2):173-80. Epub 2006 Dec 20.

PMID:
17184996
46.

Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group.

Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M, Smaaland R, Focan C, Coudert B, Humblet Y, Canon JL, Adenis A, Lo Re G, Carvalho C, Schueller J, Anciaux N, Lentz MA, Baron B, Gorlia T, Lévi F; European Organisation for Research and Treatment of Cancer Chronotherapy Group.

J Clin Oncol. 2006 Aug 1;24(22):3562-9.

PMID:
16877722
47.

Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Bourhis J, Rivera F, Mesia R, Awada A, Geoffrois L, Borel C, Humblet Y, Lopez-Pousa A, Hitt R, Vega Villegas ME, Duck L, Rosine D, Amellal N, Schueler A, Harstrick A.

J Clin Oncol. 2006 Jun 20;24(18):2866-72. Epub 2006 May 22.

PMID:
16717293
48.

In utero exposure to chemotherapy: effect on cardiac and neurologic outcome.

Van Calsteren K, Berteloot P, Hanssens M, Vergote I, Amant F, Ganame J, Claus P, Mertens L, Lagae L, Delforge M, Paridaens R, Noens L, Humblet Y, Vandermeersch B, De Muylder X.

J Clin Oncol. 2006 Apr 20;24(12):e16-7. No abstract available.

PMID:
16622256
49.

Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients.

Peters S, Voelter V, Zografos L, Pampallona S, Popescu R, Gillet M, Bosshard W, Fiorentini G, Lotem M, Weitzen R, Keilholz U, Humblet Y, Piperno-Neumann S, Stupp R, Leyvraz S.

Ann Oncol. 2006 Apr;17(4):578-83. Epub 2006 Feb 9.

PMID:
16469752
50.

Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study.

Machiels JP, Duck L, Honhon B, Coster B, Coche JC, Scalliet P, Humblet Y, Aydin S, Kerger J, Remouchamps V, Canon JL, Van Maele P, Gilbeau L, Laurent S, Kirkove C, Octave-Prignot M, Baurain JF, Kartheuser A, Sempoux C.

Ann Oncol. 2005 Dec;16(12):1898-905. Epub 2005 Oct 11.

PMID:
16219623

Supplemental Content

Loading ...
Support Center